Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MTOR Activating Mutation”

4 trials

Showing 4 of 4 results

Testing effectiveness (Phase 2)Study completedNCT03190174
What this trial is testing

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Who this might be right for
Ewing SarcomaPEComaEpithelioid Sarcoma+11 more
Sarcoma Oncology Research Center, LLC 34
Testing effectiveness (Phase 2)Study completedNCT02201212
What this trial is testing

Everolimus for Cancer With TSC1 or TSC2 Mutation

Who this might be right for
TSC1TSC2Tuberous Sclerosis Complex+1 more
Dana-Farber Cancer Institute 30
Not applicableApproved For MarketingNCT03817515
What this trial is testing

Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation

Who this might be right for
PEComa, MalignantTSC1TSC2+1 more
Aadi Bioscience, Inc.
Not applicableNot Yet RecruitingNCT07387861
What this trial is testing

PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study

Who this might be right for
Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
Assiut University 70

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation